Paclitaxel Kabi

Paclitaxel, the active ingredient in Paclitaxel Kabi, is a taxane presented as a sterile injectable solution for intravenous use. It is employed in the treatment of various solid tumours and is administered under the supervision of oncology specialists. GNH USA supplies Paclitaxel Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and clinics worldwide.

GNH USA supplies Paclitaxel Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and clinics worldwide.

Paclitaxel Kabi is a chemotherapeutic agent used in the management of several malignant neoplasms.

- Breast cancer: improves the overall response rate in metastatic and adjuvant settings. - Non‑small cell lung cancer: enhances progression‑free survival when combined with platinum‑based regimens. - Ovarian cancer: contributes to tumour reduction as part of first‑line combination therapy. - Gastric cancer: used in combination regimens for advanced disease. - Kaposi’s sarcoma: provides clinical benefit in HIV‑related cases. - Pancreatic cancer: added to multi‑drug protocols to improve response rates.

Paclitaxel may elicit a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white‑blood‑cell count increasing infection risk. - Alopecia: hair loss affecting scalp and body hair. - Peripheral neuropathy: tingling or numbness in extremities. - Nausea and vomiting: gastrointestinal upset common during infusion. - Fatigue: generalized tiredness often reported during treatment. - Myalgia: muscle aches and joint discomfort.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis‑like symptoms requiring immediate medical intervention. - Cardiotoxicity: arrhythmias or myocardial ischemia in susceptible patients. - Severe neutropenic infection: febrile neutropenia demanding urgent care. - Pulmonary toxicity: interstitial pneumonitis or acute respiratory distress. - Hepatotoxicity: marked elevation of liver enzymes and potential liver injury. - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism.

When administering Paclitaxel Kabi, clinicians should observe several safety measures.

- Pre‑medication: administer anti‑emetics and antihistamines to reduce infusion reactions. - Monitoring: conduct regular complete blood counts and liver‑function tests during therapy. - Dose adjustments: modify dosage for patients with hepatic impairment or significant bone‑marrow suppression. - Contra‑indications: avoid use in individuals with known hypersensitivity to paclitaxel or its excipients. - Pregnancy and lactation: contraind employed . - Store at 2-8°C: keep refrigerated ; protect ".

The pharmacologic interacting of Pacpac c ​    

Major   a   t  d .

t  t \